Home > Medical Devices > Australia Cardiac Resynchronization Therapy (CRT) Market Size, Share and Forecast to 2031
Straits Research

Australia Cardiac Resynchronization Therapy (CRT) Market

Australia Cardiac Resynchronization Therapy (CRT) Market: Information by Product (CRT-D and CRT-P), End-User (Hospital, Cardiac Center), and Country—Forecast till 2030

Table of Content Download Sample

Market Overview

The Australian cardiac resynchronization therapy market witnessed significant growth in the past and is expected to grow at a CAGR of 8.4% during the forecast period (2022-2030).

Cardiac resynchronization therapy (CRT) is a treatment that assists the heart in beating at the correct rate. It employs a pacemaker to restore the heartbeat's normal timing pattern. The CRT pacemaker coordinates the synchronization of the heart's upper (atria) and lower (ventricles) chambers. It also regulates the synchronization between the heart's left and right sides.

The market for cardiac resynchronization therapy (CRT) was estimated to be worth USD 5.85 billion in 2021. One of the major trends accelerating market expansion is the rapid advancement of technology. The market is expanding due to sedentary lifestyle adoption, an aging population, and increased cardiovascular disease prevalence.


  • CRT-D dominates the market by Product. 
  • Hospitals dominate the market by End-User.


Market Snapshot

Base Year:
Study Period:
8.4 %
Get more information on this report Download Sample Report

Market Dynamics

Australia Cardiac Resynchronization Therapy (CRT) Market Drivers

Technology Advancement

Ongoing improvements in Cardiac Resynchronization Therapy devices and related technologies are driving the market in Australia. Innovations including multi-point pacing, leadless Cardiac Resynchronization Therapy, and improved programming algorithms increase the effectiveness and safety of Cardiac Resynchronization Therapy. Medical professionals and patients are drawn to these technical developments, increasing demand for the newest Cardiac Resynchronization Therapy technologies and propelling market expansion.

Australia Cardiac Resynchronization Therapy (CRT) Market Restraints

Limited Access to Regional Areas

Due to Australia's large geography, receiving specialized cardiac care, particularly CRT, might be difficult. Few cardiac centers are often equipped to perform CRT implantation and follow-up care in rural and regional areas. For patients living outside large urban centers, this geographic barrier causes delays in diagnosis, poor patient treatment, and decreased access to CRT.

Health System Capacity and Workforce Challenges

A limitation may be the Australian healthcare system's ability to meet the rising demand for CRT. Particularly in rural locations, it can be difficult to find specialized medical personnel, such as cardiologists and electrophysiologists trained in CRT implantation and programming. The current workforce issues could lead to lengthier CRT procedure wait times and difficulty serving the expanding patient base.

Australia Cardiac Resynchronization Therapy (CRT) Market Opportunities

Collaborative Efforts

The introduction of Cardiac Resynchronization Therapy in Australia is accelerated by collaboration between healthcare practitioners, industry stakeholders, and research organizations. Cardiac resynchronization therapy is encouraged as a standard treatment for eligible patients by multidisciplinary teams collaborating to improve patient care and outcomes. Such cooperative initiatives promote market expansion by assisting in developing recommendations, conducting clinical investigations, and exchanging best practices.

Segmental Analysis

The Australian cardiac resynchronization therapy (CRT) market is segmented based on Product, End-User, and Country.

Based on OS, the Australian market is segmented by CRT-D and CRT-P.

CRT-D dominated the market over the forecast period.

Based on End-Users, the Australian market is segmented by Hospitals, Cardiac Centre.

Hospitals dominated the market over the forecast period.

Regional Analysis of the Cardiac Resynchronization Therapy (CRT) Market

International cardiology societies that recommend guidelines for identifying, managing, and preventing chronic heart failure in the nation include the Cardiac Society of Australia and New Zealand and the National Heart Foundation of Australia. The high prevalence of CHF, awareness campaigns by public & private health organizations, and investments by leading industry participants are anticipated to support market expansion in Australia. For instance, according to the Heart Foundation, 110,000 people in Australia have been diagnosed with heart failure. According to the Australian Institute of Health and Welfare, approximately 42,300 fatalities in 2019 were attributable to cardiovascular illnesses.

Find Regional level market intelligence here !

Top Key Players of Australia Cardiac Resynchronization Therapy (CRT) Market

  1. Abbott
  2. Boston Scientific Corporation
  3. Medtronic
  4. Biotronik SE and Co. Kg
  5. Microport Scientific Corporation
  6. LivaNova PLC
  7. Medico S.R.L.

Report Scope

Report Metric Details
CAGR 8.4%
Forecast Period 2023-2031
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered
  1. By OS
    1. CRT-D
    2. CRT-P
  2. By End-User
    1. Hospitals
    2. Cardiac Centers
    3. Others

Recent Developments

  • May 2023- Abbott announced that its PulseAl algorithm had beaten Apple Watch software at detecting atrial arrhythmias.

Australia Cardiac Resynchronization Therapy (CRT) Market Segmentations


  • CRT-D
  • CRT-P

By End-User

  • Hospitals
  • Cardiac Centers
  • Others

Frequently Asked Questions (FAQs)

What is the estimated growth rate (CAGR) of the Australian cardiac resynchronization therapy market?
The Australian cardiac resynchronization therapy market size is growing at a CAGR of 8.4% from 2023 to 2031.
Technology advancement is the key driver for the growth of the optical transport network market.
Collaborative efforts is one of the upcoming trend in the optical transport network market.
The key players in the Australian cardiac resynchronization therapy market include Abbott, Boston Scientific Corporation, Medtronic, Biotronik SE and Co. Kg, Microport Scientific Corporation, LivaNova PLC, Medico S.R.L.
Price Starts From
USD 995

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report
Report Snapshot
Looking For Custom Report ?
Check Our License Options :
Free Sample Report

"Find new revenue generation opportunities"

As featured on :

Trusted by Fortune 500
Over 30000+ subscribers